IP Library Granted Patent US 7,173,064
Granted Patent B2
US 7,173,064 · App. 10/712,546 · Granted Feb 6, 2007

Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy

Assignee: Repros Therapeutics Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,173,064
App. No.
10/712,546
Granted
Feb 6, 2007
Kind
B2
Abstract

The present invention discloses compositions and methods useful for treating wasting, especially a loss of muscle mass. The present invention also discloses compositions and methods useful for treating lipodystrophy. The compositions and methods of the present invention are particularly beneficial to HIV-infected individuals.

Claims (7)

1. A method for treating symptom of wasting in a human infected with human immunodeficiency (HIV), comprising administering to the human a composition comprising cis-clomiphene and trans-clomiphene or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients in an effective amount to treat said symptom of wasting in the human infected with HIV, wherein the weight (w/w) ratio of trans-clomiphene to cis-clomiphene is greater than 71/29.

2. The method of claim 1 wherein the composition consists essentially of trans-clomiphene or a pharmaceutically effective salt thereof and optionally one or more pharmaceutically acceptable diluents, adjuvants, carriers or excipients, in an effective amount to treat said symptom of wasting in the human infected with HIV.

3. The method of claim 2 , wherein the trans-clomiphene is in a dosage range of 1–200 mg per day.

4. The method of claim 3 , wherein the trans-clomiphene is in a dosage range of 50 mg per day.

5. The method of claim 2 , wherein the trans-clomiphene is administered in a dosage of 1.5 mg/kg per day.

6. The method of claim 2 , wherein the composition consists essentially of 12.5 mg of trans-clomiphene or a pharmaceutically effective salt thereof.

7. The method of claim 1 , wherein the composition is a capsule.

Assignments (3)
CHANGE OF NAME Recorded Nov 30, 2006
From: ZONAGEN, INC.
To: REPROS THERAPEUTICS INC.
Reel/Frame 018573/0121 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2004
From: PODOLSKI, JOSEPH S.; WIEHLE, RONALD
To: ZONAGEN, INC.
Reel/Frame 015424/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2004
From: PODOLSKI, JOSEPH S.; WIEHLE, RONALD
To: ZONAGEN, INC.
Reel/Frame 015395/0734 →
Continuity (4)
Continuation In Part 1042776800 · Apr 30, 2003
Continuation In Part PCTUS0202152400 · Jul 9, 2002
Provisional Application 6030431300 · Jul 9, 2001
Related Publication 20040171697A1 · Sep 2, 2004